Journals / Anadolu Kardiyoloji Dergisi / 2013 / Cilt: 13 - Sayı: 4

Epikardiyal adipoz doku tedavi edilmemiş hipertansif hastalarda artmış sol ventrikül kitlesi ile bağımsız ilişkilidir: Gözlemsel bir çalışma

Epicardial adipose tissue is independently associated with increased left ventricular mass in untreated hypertensive patients: An observational study

Pages
320–327
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When we divided study population into two groups according to median mean blood pressure (BP) (Mean BP ≤116 vs. >116 mmHg), EAT was the only associated factor for LVM in patients below median BP (Beta: 0.518, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Epicardial adipose tissue (EAT) secretes various inflammatory mediators and growth factor, and has endocrine and paracrine effects on myocardium and body.
📊
Key Findings & Data:Methods: The present study was cross-sectional and observational, including consecutive 107 untreated essential hypertensive patients who underwent a complete transthoracic echocardiographic examination as well as measurements of LVM and EAT.
💡
Conclusion & Impact:When we divided study population into two groups according to median mean blood pressure (BP) (Mean BP ≤116 vs. >116 mmHg), EAT was the only associated factor for LVM in patients below median BP (Beta: 0.518, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Epicardial adipose tissue (EAT) secretes various inflammatory mediators and growth factor, and has endocrine and paracrine effects on myocardium and body. We planned the present study in order to evaluate the possible relationship between EAT and left ventricular mass (LVM), a potent predictor of cardiovascular mortality and morbidity, independent of age, blood pressure and the metabolic parameters in patients with hypertension (HT). Methods: The present study was cross-sectional and observational, including consecutive 107 untreated essential hypertensive patients who underwent a complete transthoracic echocardiographic examination as well as measurements of LVM and EAT. Blood pressure, routine blood chemistry, C-reactive protein, and patient characteristics were also recorded. Univariate and then multiple linear regression analyses were used for analysis of independent variables associated with EAT. Results: LVM significantly correlated with waist circumference, EAT, glucose, uric acid, high-density lipoprotein (HDL) cholesterol, and systolic and dia- stolic blood pressure. When we divided study population into two groups according to median mean blood pressure (BP) (Mean BP ≤116 vs. >116 mmHg), EAT was the only associated factor for LVM in patients below median BP (Beta: 0.518, p

Özet

Amaç: Epikardiyal adipoz doku (EAD) çeşitli enflamatuvar mediyatörler ve büyüme faktörleri salarak miyokart ve vücut üzerine endokrin ve parakrin etkilere sahiptir. Bu çalışmada hipertansiyonlu (HT) hastalarda EAD ve kardiyovasküler morbidite ve mortalitenin güçlü bir öngörücüsü olan sol ventri- kül hipertrofisi (SVH) arasındaki olası ilişkiyi yaş, kan basıncı ve metabolik parametrelerden bağımsız olarak araştırmayı amaçladık. Yöntemler: Bu çalışma EAD ve SVH ölçümleri yanında tam bir ekokardiyografik değerlendirmesi yapılan 107 ardışık, tedavi almamış esansiyel HT has- tasında yapılan kesitsel ve gözlemsel bir çalışmadır. Kan basıncı (KB), rutin biyokimya, C-reaktif protein ve diğer hasta karakteristikleri ölçüldü. Tek değişkenli ve ardından çoklu lineer regresyon analizleri EAD ile bağımsız ilişkide olan değişkenlerin analizinde kullanıldı. Bulgular: Sol ventrikül kitlesi (SVK) bel çevresi, EAD, glikoz, ürik asit, yüksek-dansiteli lipoprotein (HDL) kolesterol, ve sistolik ve diyastolik kan basıncı ile anlamlı olarak ilişkiliydi. Çalışma popülasyonu ortanca ortalama kan basıncına göre iki gruba ayrıldığında (ortalama KB ≤116 vs. >116 mmHg), medyan KB değeri altındaki hastalarda EAD SVK’nin tek nedensel faktörüydü (Beta: 0.518, p

🔖

Cite This Article

ERDOĞAN, T., DURAKOĞLUGİL, M. E., ÇANGA, A., ERGÜL, E., UĞURLU, Y., ÇETİN, M., KOCAMAN, S. A. (2022). Epikardiyal adipoz doku tedavi edilmemiş hipertansif hastalarda artmış sol ventrikül kitlesi ile bağımsız ilişkilidir: Gözlemsel bir çalışma. Anadolu Kardiyoloji Dergisi, Cilt: 13 - Sayı: 4, 320–327. https://ajindex.com/articles/436269

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000
  2. [CrossRef] 2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990
  3. [CrossRef] 3. Verdecchia P Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001
  4. [CrossRef] 4. Verdecchia P Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001
  5. [CrossRef] 5. Gardin JM, Lauer MS. Left ventricular hypertrophy: the next treatable, silent killer? JAMA 2004
  6. [CrossRef] 6. Verdecchia P Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998
  7. [CrossRef] 7. Mathew J, Sleight P Lonn E, Johnstone D, Pogue J, Yi Q, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001
  8. [CrossRef] 8. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004
  9. [CrossRef] 9. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004
  10. [CrossRef] 10. Garavaglia GE, Messerli FH, Nunez BD, Schmieder RE, Grossman E. Myocardial contractility and left ventricular function in obese patients with essential hypertension. Am J Cardiol 1988
  11. [CrossRef] 11. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005
  12. [CrossRef] 12. Corradi D, Maestri R, Callegari S, Pastori P Goldoni M, Luong TV, et al. The ventricular epicardial fat is related to the myocardial mass in normal, ische